Bayer sells Interventional device unit to Boston Scientific
FRANKFURT (Reuters) - Bayer AG (BAYGn.DE) on Thursday said it agreed to sell its Interventional device business to Boston Scientific (BSX.N) for $415 million in cash, a deal that is expected to close in the second half of 2014.
Boston Scientific will expand its portfolio of solutions to treat peripheral vascular disease and include systems used in cardiology, radiology and peripheral vascular procedures.
"With this sale, our Medical Care division can concentrate on innovation and growth in Radiology and Diabetes Care where we already have a strong presence," Olivier Brandicourt, CEO of Bayer HealthCare AG said in a statement.
Upon completion of the transaction, Bayer Interventional will become part of the existing Boston Scientific Peripheral Interventions business, Boston Scientific said in a statement.
Bayer's Interventional business accounted for approximately $120 million in sales in 2013.
(Reporting by Edward Taylor; Editing by Arno Schuetze)
- Israel rejects ceasefire plan, source says, as death toll nears 850 |
- First Ebola victim in Sierra Leone capital on the run
- Obama tells Central American leaders most children will go home
- EU edges to economic sanctions on Russia but narrows scope |
- Bad weather seen as probable cause of Air Algerie crash